In advanced NSCLC EGFR Mutation Status test

被引：0
|
作者：
Schuette, Wolfgang [1 ]
机构：
[1] Krankenhaus Martha Maria, Klin Innere Med 2, Halle, Germany
来源：
ONKOLOGIE | 2012年 / 35卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：393 / 393
页数：1
相关论文
共 50 条
  • [21] EGFR Mutation Testing Using Liquid Biopsy Technology for Patients with Advanced EGFR-Mutant NSCLC
    Seitz, Jan
    Moskalev, Evgeny A.
    Fuchs, Florian
    Haller, Florian
    Hartmann, Arndt
    [J]. LABORATORY INVESTIGATION, 2018, 98 : 750 - 750
  • [22] EGFR Mutation Testing Using Liquid Biopsy Technology for Patients with Advanced EGFR-Mutant NSCLC
    Seitz, Jan
    Moskalev, Evgeny A.
    Fuchs, Florian
    Haller, Florian
    Hartmann, Arndt
    [J]. MODERN PATHOLOGY, 2018, 31 : 750 - 750
  • [23] TREATMENT OF NSCLC PATIENTS WITH EGFR MUTATION
    Yang, J. C. -H.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 29 - 29
  • [24] Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
    Wen, Miaomiao
    Xia, Jinghua
    Sun, Ying
    Wang, Xuejiao
    Fu, Xianghui
    Zhang, Yanning
    Zhang, Zhipei
    Zhou, Yongan
    Li, Xiaofei
    [J]. BIOLOGICS-TARGETS & THERAPY, 2018, 12 : 183 - 190
  • [25] Observational study of rebiopsy in EGFR-TKI-resistant patients with EGFR mutation-positive advanced NSCLC
    Kenichi Koyama
    Satoru Miura
    Satoshi Watanabe
    Satoshi Shoji
    Jun Koshio
    Yoshiki Hayashi
    Daisuke Ishikawa
    Ko Sato
    Takao Miyabayashi
    Masaaki Okajima
    Takeshi Ota
    Tomohiro Tanaka
    Naoya Matsumoto
    Hideyuki Kuriyama
    Tetsuya Abe
    Koichiro Nozaki
    Kosuke Ichikawa
    Rie Kondo
    Hiroshi Tanaka
    Toshiaki Kikuchi
    [J]. Scientific Reports, 12
  • [26] Progression patterns at RECIST PD during EGFR-TKIs in advanced NSCLC patients harboring EGFR mutation
    Yoshida, Tatsuya
    Yoh, Kiyotaka
    Goto, Koichi
    Matsumoto, Shingo
    Umemura, Shigeki
    Niho, Seiji
    Ohmatsu, Hironobu
    Ohe, Yuichiro
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [27] Impacts of EGFR mutation and EGFR-TKIs on incidence of brain metastases in advanced non-squamous NSCLC
    Wang, Bao-Xiao
    Ou, Wei
    Mao, Xiao-Yong
    Liu, Zui
    Wu, Hui-Qi
    Wang, Si-Yu
    [J]. CLINICAL NEUROLOGY AND NEUROSURGERY, 2017, 160 : 96 - 100
  • [28] Time to EGFR-TKI Treatment for Patients with Advanced NSCLC and EGFR Activating Mutation in a Tertiary Cancer Center
    Le Guevelou, Jennifer
    Dugue, Audrey
    Richard, Nicolas
    Dubos, Catherine
    Do, Pascal
    Danhier, Serge
    Lerouge, Delphine
    Bonneau, Jessica
    Blanc, Cecile
    Gervais, Radj
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1229 - S1229
  • [29] Observational study of rebiopsy in EGFR-TKI-resistant patients with EGFR mutation-positive advanced NSCLC
    Koyama, Kenichi
    Miura, Satoru
    Watanabe, Satoshi
    Shoji, Satoshi
    Koshio, Jun
    Hayashi, Yoshiki
    Ishikawa, Daisuke
    Sato, Ko
    Miyabayashi, Takao
    Okajima, Masaaki
    Ota, Takeshi
    Tanaka, Tomohiro
    Matsumoto, Naoya
    Kuriyama, Hideyuki
    Abe, Tetsuya
    Nozaki, Koichiro
    Ichikawa, Kosuke
    Kondo, Rie
    Tanaka, Hiroshi
    Kikuchi, Toshiaki
    [J]. SCIENTIFIC REPORTS, 2022, 12 (01)
  • [30] Bisphosphonates enhance EGFR-TKIs efficacy in advanced NSCLC patients with EGFR activating mutation: A retrospective study
    Huang, Chu-ying
    Wang, Li
    Feng, Cheng-jun
    Yu, Ping
    Cai, Xiao-hong
    Yao, Wen-xiu
    Xu, Yong
    Liu, Xiao-ke
    Zhu, Wen-jiang
    Wang, Yan
    Zhou, Jin
    Lu, You
    Wang, Yong-sheng
    [J]. ONCOTARGET, 2016, 7 (41): : 66480 - 66490
12345